Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.

<h4>Background</h4>Targeted therapies, associated with standard chemotherapies, have improved breast cancer care. However, primary and acquired resistances are frequently observed and the development of new concepts is needed. High-throughput approaches to identify new active and safe molecules with...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Lynda Mezil, Carole Berruyer-Pouyet, Olivier Cabaud, Emmanuelle Josselin, Sébastien Combes, Jean-Michel Brunel, Patrice Viens, Yves Collette, Daniel Birnbaum, Marc Lopez
Format:	Artigo
Język:	Inglês
Wydane:	Public Library of Science (PLoS) 2012-01-01
Seria:	PLoS ONE
Dostęp online:	https://doi.org/10.1371/journal.pone.0043409
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!